When was Inozyme Pharma founded?

Inozyme Pharma was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is Inozyme Pharma located?

Inozyme Pharma is headquartered in Cambridge, United States.

Who is the current CEO of Inozyme Pharma?

Axel Bolte of Inozyme Pharma. They have also founded 1 company.

How many employees does Inozyme Pharma have?

As of Sep 05, 2025, the latest employee count at Inozyme Pharma is 58.

Is Inozyme Pharma a funded company?

Inozyme Pharma is a funded company, having raised a total of $116M across 2 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 15, 2017.

How much is Inozyme Pharma worth?

The last known valuation of Inozyme Pharma was $***** as of May 16, 2025.

When was the latest funding round of Inozyme Pharma?

Inozyme Pharma's latest funding was a $***** Series A round on Apr 10, 2019, with participation from 9 investors. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $711M in funding in 2026 to date.

Where does Inozyme Pharma rank among its competitors?

Inozyme Pharma ranks 91st amongst 278 active competitors, of which 78 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Inozyme Pharma?

Inozyme Pharma's top competitors include BridgeBio, Alnylam and Alexion. Among them, BridgeBio secured the most recent funding round in April, 2024.

Inozyme Pharma - 2026 Company Profile, Team, Funding, Competitors & Financials

Inozyme Pharma is an acquired company based in Cambridge (United States), founded in 2016 by Axel Bolte. It operates as a Developer of treatments for rare and debilitating metabolic diseases. Inozyme Pharma has raised $116M in funding from investors like Sofinnova Investments, Longitude Capital and Pivotal bioVenture Partners, with last known valuation of $*****. The company has 278 active competitors, including 78 funded and 96 that have exited. Its top competitors include companies like BridgeBio, Alnylam and Alexion.

Company Details

Developer of treatments for rare and debilitating metabolic diseases. The company's product line include INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy to increase PPi and adenosine, enabling the potential treatment of multiple diseases caused by deficiencies in metabolites.

Website: inozyme.com
Email ID: *****@inozyme.com
Phone Number: +1 **********

Key Metrics

Founded Year

2016

Location

Cambridge, United States

Stage

Acquired

Total Funding

$116M in 2 rounds

Latest Funding Round

Series A, Apr 10, 2019, $*****

Last Known Valuation

$***** as on May 16, 2025

Investors

Sofinnova Investments & 11 more

Ranked

91^st among 278 active competitors

Employee Count

58 as on Sep 05, 2025

Similar Companies

BridgeBio & 312 more

Exit Details

Acquired by BioMarin Pharmaceutical (May 16, 2025)

View Inozyme Pharma's full profile

Inozyme Pharma is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
INOZYME PHARMA, INC. CIN: 1693011 , United States, Active	Sep 10, 2015	-	59 (As on Dec 31, 2023)	-
Inozyme Pharma, Inc. CIN: 001t000000WoJL2AAN , United States, Active	Sep 10, 2018	-	-	-

Inozyme Pharma got acquired by BioMarin Pharmaceutical on May 16, 2025 at an acquisition amount of $*****.

Click here to take a look at Inozyme Pharma's acquisition in detail

Inozyme Pharma has raised a total funding of $116M over 2 rounds. Its first funding round was on Nov 15, 2017. Its latest funding round was a Series A round on Apr 10, 2019 for $*****. 9 investors participated in its latest round. Inozyme Pharma has 12 institutional investors.

Here is the list of recent funding rounds of Inozyme Pharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 10, 2019	4118934	Series A	2433768	3773328	4145017	5307701
Nov 15, 2017	4734286	Series A	1358347	3863174	Longitude Capital	New Enterprise Associates & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of Inozyme Pharma's funding rounds and investors

The founders of Inozyme Pharma is Axel Bolte. Axel Bolte is the CEO of Inozyme Pharma.

Here are the details of Inozyme Pharma's key team members:

Axel Bolte: Co-Founder & CEO of Inozyme Pharma.

View details of Inozyme Pharma's Founder profiles and Board Members

Inozyme Pharma's employee count trend

Inozyme Pharma has 58 employees as of Sep 25. Here is Inozyme Pharma's employee count trend over the years:

Uncover Inozyme Pharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Inozyme Pharma include BridgeBio, Alnylam and Alexion. Here is the list of Top 10 competitors of Inozyme Pharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	79/100
4th	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 8 others	70/100
10th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	66/100
91st	Inozyme Pharma 2016, Cambridge (United States), Acquired	Developer of treatments for rare and debilitating metabolic diseases	$116M	Cowen, Novo Holdings & 10 others	47/100